Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ridaforolimus in recurrent endometrial cancer
NCT00770185Phase 2Completed
- Sponsor
- Canadian Cancer Trials Group
- Start
- Nov 2008
- Primary completion
- Mar 2012
- Modality
- Classical Binding Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of ridaforolimus in endometrial cancer (EC), sponsored by Canadian Cancer Trials Group. Started Nov 2008; status: completed.
02
Drugs
ridaforolimus
03
Conditions
endometrial cancer (EC)
Beyond the preview
Go deeper on NCT00770185.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00770185.